PSA testing for prostate cancer screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.BMC cancer · 2024
   Article
2. Development and validation of a clinic machine-learning nomogram for the prediction of risk stratifications of prostate cancer based on functional subsets of peripheral lymphocyte.Journal of translational medicine · 2023
   Article
3. Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection.The Annals of thoracic surgery · 2016
   Article
4. What's new in screening in 2015?Current opinion in urology · 2016
   Review
5. Epigenetics and Precision Oncology.Cancer journal (Sudbury, Mass.)
   Review

Corrections and comments

• Commented on by
  PSA testing for prostate cancer screening--authors' reply.2015
• Comment on
  Prevention and early detection of prostate cancer.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as